Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional mitomycin C versus interferon alpha-2b for primary pterygium
PACTR202302902720138Phase 4Recruiting
- Sponsor
- Dr. Maryam Fashola
- Start
- Feb 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mitomycin c and interferon alfa-2b in pterygium (2 arms), sponsored by Dr. Maryam Fashola. Primary endpoint: Reduction in size of pterygium. Started Feb 2023; status: recruiting.
02
Drugs
mitomycin cinterferon alfa-2b
03
Conditions
pterygium
Beyond the preview
Go deeper on PACTR202302902720138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202302902720138.